Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 6 other studies
1,708people in the Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus trial, from 2019
636of them with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
liraglutide
control group
Probably lowered stroke recurrence after 90 days−44%
Probably raised excellent functional outcomes1.9×
randomisedthe abstract, start to end
… stroke recurrence (hazard ratio, 0.56; 95% CI, 0.34-0.91; P = .02).
… functional outcomes (odds ratio, 1.95; 95% CI, 1.28-3.00; P = .002).
← favours treatmentfavours comparator →
could be chanceStroke recurrence (ischemic or hemorrhagic) after 90 daysliraglutide vs control group
HR 0.560.34–0.91
Excellent functional outcomes (modified Rankin Scale score, ≤1)liraglutide vs control group
OR 1.951.28–3.00
GLP-1 receptor agonistsCardiovascular eventsAdverse events & safety
GLP-1 receptor agonists × adverse events & safetyharms?mixed
unlikelylikely
0.000.00 without it
GLP-1 receptor agonists × cardiovascular eventshelps?mixed
unlikelylikely
0.500.78 without it
← favours treatmentfavours comparator →
1 / 6